Moderna begins testing on its new COVID-19 vaccine candidate
Company says candidate could be stored, shipped in refrigerators instead of freezers
Moderna Inc. said on Monday it had dosed the first participant in an early-stage study of a new COVID-19 vaccine candidate that could potentially be stored and shipped in refrigerators instead of freezers.
The company said its new candidate could make it easier for distribution, especially in developing countries where supply chain issues could hamper vaccination drives.
The early-stage study will assess the safety and immunogenicity of the next-generation vaccine, designated as mRNA-1283, at three dose levels, and will be given to healthy adults either as a single dose, or in two doses 28 days apart, the company said.
We just announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, our next generation COVID-19 vaccine candidate. Read more: <a href="https://t.co/jRR5FLAgiW">https://t.co/jRR5FLAgiW</a> <a href="https://t.co/ONXeHSTCjI">pic.twitter.com/ONXeHSTCjI</a>
—@moderna_txModerna also plans to evaluate the new vaccine, mRNA-1283, as a potential booster shot in future studies.
Last week, Moderna began dosing the first participants in a study testing COVID-19 booster vaccine candidates targeting the variant, known as B.1.351, that was first detected in South Africa.
The booster vaccine candidates, designated mRNA-1273.351, will be tested in a trial of both a variant-specific shot and a multivalent shot, according to the company's announcement.
Moderna's first vaccine (mRNA-1273) was approved for use by Health Canada on Dec. 23.
With files from CBC News
